Non-V600BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 35, Issue 23, 2017, Pages 2624-2630

  Jones, Jeremy C ^a   Renfro, Lindsay A ^a   Al Shamsi, Humaid O ^b   Schrock, Alexa B ^c   Rankin, Andrew ^c   Zhang, Ben Y ^a   Kasi, Pashtoon M ^a   Voss, Jesse S ^a   Leal, Alexis D ^a   Sun, James ^c   Ross, Jeffrey ^c   Ali, Siraj M ^c   Hubbard, Joleen M ^a   Kipp, Benjamin R ^a   McWilliams, Robert R ^a   Kopetz, Scott ^b   Wolff, Robert A ^b   Grothey, Axel ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c FOUNDATION MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; CODON;

ADULT; AGED; CANCER GRADING; CANCER PROGNOSIS; CODON; COHORT ANALYSIS; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC IDENTIFICATION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MOLECULAR GENETICS; MULTICENTER STUDY; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VERY ELDERLY; AGE; CLINICAL TRIAL; COLORECTAL TUMOR; GENETICS; METASTASIS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; SEX DIFFERENCE; SURVIVAL RATE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CODON; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL RATE;

EID: 85028703720     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.71.4394     Document Type: Conference Paper

References (24)

1. Douillard JY, Oliner KS, Siena S, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369: 1023-1034, 2013
2. Pietrantonio F, Petrelli F, Coinu A, et al: Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis. Eur J Cancer 51: 587-594, 2015
3. Richman SD, Seymour MT, Chambers P, et al: KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: Results from the MRC FOCUS trial. J Clin Oncol 27: 5931-5937, 2009
4. Tran B, Kopetz S, Tie J, et al: Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117:4623-4632, 2011
5. Van Cutsem E, Köhne C-H, Láng I, et al: Cetuximab plus irinotecan, fluorouracil, and leuco-vorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019, 2011
6. Allegra CJ, Rumble RB, Hamilton SR, et al: Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol 34:179-185, 2016
7. Cremolini C, Di Bartolomeo M, Amatu A, et al: BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Ann Oncol 26:2092-2097, 2015
8. Frampton GM, Fichtenholtz A, Otto GA, et al: Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31:1023-1031, 2013
9. Grambsch PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515-526, 1994
10. Little RJA, Rubin DB: Statistical Analysis With Missing Data (ed 2). Hoboken, NJ, Wiley, 2002
11. Harrell FE: Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY, Springer, 2001
12. Steyerberg EW: Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. New York, NY, Springer, 2009
13. The R Core Team: R: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2008
14. Wan PT, Garnett MJ, Roe SM, et al: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-867, 2004
15. Zheng G, Tseng LH, Chen G, et al: Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. BMC Cancer 15:779, 2015
16. Noeparast A, Teugels E, Giron P, et al: Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of tra-metinib and dabrafenib. Oncotarget 10.18632/ oncotarget.11635 [epub ahead of print on August 26, 2016]
17. Loupakis F, Cremolini C, Masi G, et al: Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371: 1609-1618, 2014
18. Heinemann V, von Weikersthal LF, Decker T, et al: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol 15:1065-1075, 2014
19. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002
20. Forbes SA, Beare D, Gunasekaran P, et al: COSMIC: Exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res 43:D805-D811, 2015
21. Rajakulendran T, Sahmi M, Lefrançois M, et al: A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461:542-545, 2009
22. Heidorn SJ, Milagre C, Whittaker S, et al: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140: 209-221, 2010
23. Lavoie H, Thevakumaran N, Gavory G, et al: Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat Chem Biol 9: 428-436, 2013
24. Freeman AK, Ritt DA, Morrison DK: Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol Cell 49: 751-758, 2013